Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEUTON: Aflibercept Treat-and-Extend for Macular Edema Secondary to CRVO
2014-000975-21Phase 4Completed
- Sponsor
- RetinaPlus
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in central retinal vein occlusion with macular edema, sponsored by RetinaPlus. Primary endpoint: Mean change in BCVA at 12 months. Started Jun 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on 2014-000975-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000975-21.